Hiroya Tamai1, Naoshi Nishina2, Jun Kikuchi3, Keisuke Izumi3,4, Kotaro Otomo5, Keiko Yoshimoto3, Kunihiro Yamaoka6, Tsutomu Takeuchi3, Yuko Kaneko3. 1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. h.tamai@keio.jp. 2. Nishina Medical Clinic, Nagano, Japan. 3. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. 4. Division of Rheumatology, Department of Medicine, National Tokyo Medical Center, Tokyo, Japan. 5. Otomo Rheumatology Clinic, Tokyo, Japan. 6. Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan.
Abstract
INTRODUCTION: /objectives Several biological disease-modifying anti-rheumatic drugs (bDMARDs) have been widely used for the management of rheumatoid arthritis (RA). These drugs target different molecules important for the pathophysiology of RA; however, only a few studies have compared the effects of these biological drugs on cytokines and bone metabolic markers. The main aim of this study is to clarify the effects of bDMARDs with different modes of action on the cytokine and bone metabolic marker levels in patients with RA. METHODS: Patients with RA who were initiated on infliximab, tocilizumab, or abatacept as the first bDMARD were prospectively enrolled in this study. Serum cytokine and bone metabolic marker levels were measured longitudinally, and changes in their levels were compared. RESULTS: A total of 174 patients were enrolled in this study, with 55, 70, and 49 patients in the infliximab, tocilizumab, and abatacept groups, respectively. At six months, despite the similar clinical effectiveness of the three drugs, changes in the cytokine and bone metabolic marker levels were distinct; interferon-γ and tumor necrosis factor-α levels were significantly increased with infliximab, interleukin-6 levels were increased with tocilizumab, and interleukin-1β and interleukin-8 levels were increased with abatacept treatment. Bone-specific alkaline phosphatase and osteocalcin levels increased more significantly with tocilizumab than with infliximab, while osteopontin and osteonectin levels decreased with infliximab treatment. CONCLUSIONS: bDMARDs with different modes of action exert different effects on the cytokine and bone metabolic marker levels in patients with RA.
INTRODUCTION: /objectives Several biological disease-modifying anti-rheumatic drugs (bDMARDs) have been widely used for the management of rheumatoid arthritis (RA). These drugs target different molecules important for the pathophysiology of RA; however, only a few studies have compared the effects of these biological drugs on cytokines and bone metabolic markers. The main aim of this study is to clarify the effects of bDMARDs with different modes of action on the cytokine and bone metabolic marker levels in patients with RA. METHODS: Patients with RA who were initiated on infliximab, tocilizumab, or abatacept as the first bDMARD were prospectively enrolled in this study. Serum cytokine and bone metabolic marker levels were measured longitudinally, and changes in their levels were compared. RESULTS: A total of 174 patients were enrolled in this study, with 55, 70, and 49 patients in the infliximab, tocilizumab, and abatacept groups, respectively. At six months, despite the similar clinical effectiveness of the three drugs, changes in the cytokine and bone metabolic marker levels were distinct; interferon-γ and tumor necrosis factor-α levels were significantly increased with infliximab, interleukin-6 levels were increased with tocilizumab, and interleukin-1β and interleukin-8 levels were increased with abatacept treatment. Bone-specific alkaline phosphatase and osteocalcin levels increased more significantly with tocilizumab than with infliximab, while osteopontin and osteonectin levels decreased with infliximab treatment. CONCLUSIONS: bDMARDs with different modes of action exert different effects on the cytokine and bone metabolic marker levels in patients with RA.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: Joel M Kremer; Harry K Genant; Larry W Moreland; Anthony S Russell; Paul Emery; Carlos Abud-Mendoza; Jacek Szechinski; Tracy Li; Zhiyu Ge; Jean-Claude Becker; Rene Westhovens Journal: Ann Intern Med Date: 2006-06-20 Impact factor: 25.391
Authors: Danielle Diarra; Marina Stolina; Karin Polzer; Jochen Zwerina; Michael S Ominsky; Denise Dwyer; Adelheid Korb; Josef Smolen; Markus Hoffmann; Clemens Scheinecker; Desiree van der Heide; Robert Landewe; Dave Lacey; William G Richards; Georg Schett Journal: Nat Med Date: 2007-01-21 Impact factor: 53.440
Authors: R Axmann; S Herman; M Zaiss; S Franz; K Polzer; J Zwerina; M Herrmann; J Smolen; G Schett Journal: Ann Rheum Dis Date: 2008-01-18 Impact factor: 19.103
Authors: Nicole C Walsh; Susan Reinwald; Catherine A Manning; Keith W Condon; Ken Iwata; David B Burr; Ellen M Gravallese Journal: J Bone Miner Res Date: 2009-09 Impact factor: 6.741